A larger cohort of patients could give us insight into the degree of variability between AML patients, especially with different mutation patterns, as we have only used ctDNA from two genes commonly mutated in AML, NPM1 and IDH2. To analyze more than one mutation within the same patient over time a next-generation sequencing (NGS) panel from liquid biopsies would be required for AML, comparable to those commercially available for solid tumors and already used in precision oncology programs when tumor biopsies cannot be obtained.45 Here, IDH2 is linked to acute myeloid leukemia.